TNX-102 SL Improves Sleep, Cuts Pain & Fatigue in Fibromyalgia
Okay, here’s a breakdown of the provided text, summarizing the key information about TNX-102 SL for fibromyalgia.
Key Takeaways:
* FDA approval: TNX-102 SL was approved by the FDA in August 2025 for the treatment of fibromyalgia in adults. This is the first new treatment approved for fibromyalgia in over 15 years and the fourth overall.
* Mechanism: TNX-102 SL targets sleep-related neurophysiology, aiming to address multiple core symptoms of fibromyalgia (pain, sleep disturbance, fatigue, impaired functioning).
* Trial Design: A Phase 3, double-blind, placebo-controlled trial (NCT05273749) involving 457 adults with fibromyalgia at 33 US sites.
* Dosage: Patients received 2.8 mg nightly for the first 2 weeks, then 5.6 mg nightly for 12 weeks.
* Primary Endpoint: Change from baseline to week 14 in weekly average pain intensity (measured by a daily numeric rating scale).
* Results:
* TNX-102 SL demonstrated a statistically significant and clinically meaningful reduction in pain compared to placebo (LS mean difference of -0.7, *P* < .001).
* Improvements were seen as early as week 1 and sustained throughout the treatment period.
* A higher percentage of patients treated with TNX-102 SL achieved at least a 30% (45.9% vs 27.1%) and 50% (22.5% vs 13.3%) reduction in pain.
* Patient Population: The trial population was primarily female (95.4%) and White (84.6%), with an average age of 49.4 years and a mean fibromyalgia duration of 9.2 years. Most had not previously used FDA-approved fibromyalgia therapies.
* Fibromyalgia Characteristics: The text highlights that fibromyalgia is a nociplastic pain syndrome characterized by widespread chronic pain, nonrestorative sleep, fatigue, and impaired daily functioning. Current treatment options are limited.
* Secondary Endpoints: The treatment showed consistent benefits across multiple secondary endpoints (though specific details aren’t provided in this excerpt).
In essence, the text presents TNX-102 SL as a promising new treatment option for fibromyalgia, demonstrating significant pain reduction and improvements in other key symptoms in a well-designed clinical trial.